VP of Regulatory Affairs Salary Guide 2026: Compensation Benchmarks by Company Size and Industry

As Global Head of Research & Leadership Advisory at JRG Partners, I present this VP of Regulatory Affairs salary guide for 2026 for the boards and leaders responsible for pricing the VP of Regulatory Affairs seat correctly. Set the package too low and you screen out the operators you need; structure it poorly and you attract candidates optimizing for the wrong things. The benchmarks below are directional and must be tuned to your scale, ownership, industry, and market before an offer is built on them.

What Drives VP of Regulatory Affairs Compensation in 2026

VP of Regulatory Affairs compensation reflects one of the economy’s most structurally undersupplied leadership markets: every drug, biologic, device, and diagnostic requires regulatory leadership, agency-experienced talent is finite, and demand compounds with every scientific advance. Approval-pathway experience drives pricing, novel-modality submissions, first-in-class approvals, global filing command, and premiums attach to agency relationships that are earned rather than claimed and to submission records verifiable in public databases.

VP of Regulatory Affairs Salary Benchmarks by Company Size

Directional 2026 United States benchmarks for VP of Regulatory Affairs compensation appear below by revenue tier. Adjust for industry, geography, and mandate before building an offer on them.

Company Revenue	Base Salary Range	Target Total Cash	Typical Total Direct Compensation
Under $25M (venture / early stage)	$125,000 – $175,000	$150,000 – $250,000	Cash plus meaningful early-stage equity
$25M – $100M	$175,000 – $225,000	$200,000 – $325,000	$250,000 – $425,000
$100M – $500M	$200,000 – $275,000	$250,000 – $400,000	$350,000 – $725,000
$500M – $1B	$250,000 – $325,000	$300,000 – $475,000	$550,000 – $1.2M
$1B – $5B (often public)	$300,000 – $425,000	$350,000 – $625,000	$1.1M – $2.7M
Over $5B (large-cap public)	$400,000 – $550,000	$475,000 – $800,000	$2.4M – $6M

Read the bands as calibration, not prescription: step-up candidates price in the lower half, proven operators with directly relevant miles at the top or above.

Benchmarks by Ownership Structure

Clinical-stage biotechs pair moderate cash with 0.4-1% equity, the seat frequently diligence-critical for every financing. Large pharma pays the cash ceiling for global regulatory command. Device and diagnostics companies price submission-cycle experience sharply, and consultancy alternatives discipline the whole market, credible candidates always have one.

Industry Differentials That Persist in 2026

Biopharma sets the ceiling with novel-modality premiums; medical device and diagnostics follow closely; food, cosmetics, and general-regulated industries price 25-40% below the life-sciences market.

Geographic Differentials: Narrower, Not Gone

Geography still moves the number, though less than it once did. Coastal apex markets, New York, the Bay Area, Boston, price 15-25% above national medians; the large Sun Belt and Midwest hubs sit within 5-10% of them; and smaller regional markets run 10-15% below, which lowers local budgets but obliges thoughtful package construction whenever talent must be imported.

Structuring the Package: Beyond the Benchmarks

Package design does work that raw benchmarks cannot. Effective structures keep annual incentives concentrated and auditable, extend long-term vesting across three to four years with performance conditions attached, and frame the whole as one coherent proposition: succeed at this specific mandate and here, concretely, is what it is worth to you. Plans should tie to submission and approval milestones alongside quality-of-interaction outcomes, avoiding calendar-driven metrics that pressure teams toward premature filings.

Common Pricing Mistakes to Avoid

Watch for the classic mispricing patterns: incumbent-anchored offers that ignore how the role has been rescoped; base-to-total-compensation comparisons that understate the candidate’s real alternative; incentive structures invented in the final week rather than designed at kickoff; and benchmarks borrowed from the wrong market or the wrong company scale. Search post-mortems trace a remarkable share of lost finalists to one of these four.

How to Use These Benchmarks in a Live Search

Used well, benchmarks are the start of a disciplined sequence: mandate first, then range, then candidates. Anchor to the role as now scoped rather than to history, secure compensation-committee approval before finalists are in play, stress-test the structure against the candidate’s best alternative offer, and let the interview process verify that the experience being priced is real rather than well-narrated. For the verification and scoping steps, our VP of Regulatory Affairs interview guide and our VP of Regulatory Affairs job description template are built to pair with this guide.

The Bottom Line for Boards and CEOs

The pattern across hundreds of searches is consistent: prepared employers close their preferred candidates at fair prices, while casual benchmarkers either lose finalists to better-constructed offers or win them at unnecessary premiums. Use this VP of Regulatory Affairs salary guide as the baseline, and invest your real effort in the package architecture your specific mandate demands.